Literature DB >> 21431845

Hormone therapy in perimenopause and postmenopause (HT). Interdisciplinary S3 Guideline, Association of the Scientific Medical Societies in Germany AWMF 015/062-short version.

Olaf Ortmann1, Martina Dören, Eberhard Windler.   

Abstract

This short version of the interdisciplinary S3 guideline on hormone therapy in peri- and postmenopause (HT) is intended as a decision-making instrument for physicians and women considering HT. It is designed to assist daily practice. This short version summarises the long version that contains detailed information about the development of the guideline, particularly about establishing the evidence levels. The statements and recommendations, quoted completely, are marked with the relevant levels of evidence (LoE) and grades of recommendation. The classification system from the Centre for Evidence-based Medicine in Oxford was used in this guideline (see "Attachment").

Entities:  

Mesh:

Year:  2011        PMID: 21431845      PMCID: PMC3133644          DOI: 10.1007/s00404-011-1878-x

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  4 in total

Review 1.  The treatment of climacteric symptoms.

Authors:  Olaf Ortmann; Claus Lattrich
Journal:  Dtsch Arztebl Int       Date:  2012-04-27       Impact factor: 5.594

2.  Vaginal Estrogen Therapy for Patients with Breast Cancer.

Authors:  M Moegele; S Buchholz; S Seitz; C Lattrich; O Ortmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-10       Impact factor: 2.915

3.  Human umbilical cord mesenchymal stem cells improve the reserve function of perimenopausal ovary via a paracrine mechanism.

Authors:  Jia Li; QiuXian Mao; JingJun He; HaoQing She; Zhi Zhang; ChunYan Yin
Journal:  Stem Cell Res Ther       Date:  2017-03-09       Impact factor: 6.832

Review 4.  Therapeutic Potential of HUMSCs in Female Reproductive Aging.

Authors:  Qiaojuan Mei; Hongbei Mou; Xuemei Liu; Wenpei Xiang
Journal:  Front Cell Dev Biol       Date:  2021-05-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.